)
)
2Seventy Bio Investor Relations Material
Latest events
Q3 2024
2Seventy Bio
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from 2Seventy Bio Inc
Access all reports
2Seventy Bio Inc. (NASDAQ: TSVT) is a biotechnology company specializing in cell and gene therapy with a focus on developing and commercializing treatments for cancer within the United States. The company's research and development efforts are centered on advancing a pipeline of chimeric antigen receptor-T cell (CAR-T) product candidates, including idecabtagene vicleucel (ide-cel or Abecma) and bb21217, aimed at treating multiple myeloma. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
TSVT
Country
🇺🇸 United States